Clozapine & LAI Virtual Forum
October 5th, 2022 | 4:00 – 4:45 pm ET

The Clozapine & LAI Virtual Forum is an all-new, peer-to-peer, interactive dialogue between psychiatrists, nurse practitioners, and other prescribing clinicians. It is informal, no registration required — just join our Zoom call and share your challenges and questions on the month's trending topic around either clozapine or LAIs.

**TODAY’S TOPIC:**
Long-Acting Injectable Antipsychotic Medications and Troubleshooting Insurance Coverage
MODERATORS

**Robert Cotes, MD**  
SMI Adviser Physician Expert; Emory University  
Dr. Robert Cotes, MD, is an Associate Professor at Emory University School of Medicine in the Department of Psychiatry and Behavioral Sciences. He has interest in clozapine, characterizing persistent symptoms of schizophrenia, understanding cardiometabolic side effects of antipsychotic medications, and first episode psychosis.

**Donna Rolin, PhD, APRN**  
SMI Adviser Nursing Expert; University of Texas, Austin  
Dr. Donna Rolin is Clinical Associate Professor and the Director of the Psychiatric Mental Health Nurse Practitioner program at the University of Texas with 23 years of experience in psychiatric nursing, including inpatient, community, forensic, and older adult settings.

**Megan Ehret, PharmD, MS, BCPP**  
SMI Adviser Pharmacy Consultant, University of Maryland  
Dr. Megan Ehret is a Professor at University of Maryland School of Pharmacy in the Department of Pharmacy Practice and Science. She is a Past-President of the College of Psychiatric and Neurologic Pharmacists. Her current interests include psychotropic medication adherence and the incorporation of the psychiatric pharmacist in practice.
Discussion Questions for Virtual Forum: Long-Acting Injectable Antipsychotic Medications and Troubleshooting Insurance Coverage

1. Have you experienced a rejection from an insurance company when prescribing a LAI?

2. Have you completed a prior authorization form when prescribing a LAI?

3. Which medication have you received the majority of insurance coverage rejections on when prescribing a LAI?
   - Risperidone Microspheres (Consta)
   - Paliperidone Palmitate (Sustenna, Trinza, or Hafyera)
   - Risperidone subcutaneous (Perseris)
   - Olanzapine pamoate (Relprevv)
   - Aripiprazole monohydrate (Maintena)
   - Aripiprazole lauroxel (Aristada or Initio)
Insurance Language

• Formulary
  • Tier I/Preferred Medication
  • Tier II
  • Non-preferred medication

• Prior Authorization
  • Requirements
  • Appeals
Prescriber Assistance Initiatives

• [https://www.aristada.com/copay-savings](https://www.aristada.com/copay-savings)
• [https://www.janssencarepath.com/hcp/invega-sustenna](https://www.janssencarepath.com/hcp/invega-sustenna)
• [https://www.otsukapatientsupport.com/abilify-maintena/pay-for-treatment](https://www.otsukapatientsupport.com/abilify-maintena/pay-for-treatment)
Other Options for Assistance

• Co-pay coupons
• Samples
• Discount cards
Case Study

• 35 year old patient with schizophrenia who was loaded with Invega Sustenna 234 mg and 156 mg while inpatient.
• Patient has follow up with provider for follow up appointment in 4 weeks
• Invega Sustenna is not listed on formulary plan
• Prior authorization is completed by outpatient psychiatrist
Welcome to the Long-Acting Injectable (LAI) Center of Excellence (COE)

SMI Adviser created the LAI COE to promote the safe and effective use of LAIs. The ultimate goal of this effort is to improve the lives of individuals who have schizophrenia, schizoaffective, and bipolar disorders. The LAI COE provides clinicians with training opportunities, technical assistance, and vetted resources. These include:

- Live and on-demand webinars
- Virtual Learning Collaboratives
- Virtual Forums
- Email listserv
- On-demand consultations
- Intensive consultation to sites or communities
- Clinical tips and resources

The LAI COE is led by SMI Nursing Expert, Donna Rolin, PhD, APRN, SMI Adviser Physician Expert, Robert Cotes, MD, and SMI Adviser content partner, National Association of State Mental Health Program Directors (NASMHPD), and supported by members of the LAI Workgroup.

For individual and family resources on using long-acting injectables, visit the individual and family Knowledge Base.

© 2019 American Psychiatric Association. All rights reserved.
FEEDBACK
Please help us improve the Clozapine & LAI Virtual Forum by completing this survey: http://smiadviser.org/forumfeedback

Pre-submit Cases
www.smiadviser.org/vfcases

UPCOMING VIRTUAL FORUM

Clozapine Topic:
Management of Clozapine Induced Constipation
with guest Dr. Susanna Every-Palmer from New Zealand
11/2/22 @ 4:00-4:45pm ET

For additional questions and resources – join the Clozapine and LAI Centers of Excellence Exchange Community
- www.smiadviser.org/cloz_lai_signup